The current experiments used acute drug dosing to study behavioral pharmacology in Fmr1-/Y mice, but one of the broader aims of these investigations is to determine if selective drugs acting on dopamine, glutamate, or acetylcholine receptors can ameliorate ongoing abnormal behaviors, with the ultimate goal of developing better treatments for individuals with FXS. The gene discussed is FMR1; the disease is fragile X syndrome.